Recently, Sema3A-mediated growth cone collapse has been suggested to have connection with a major drug target of Alzheimer's disease: BACE1 (beta-site amyloid precursor protein-cleaving enzyme 1). This evidence concerns the gene BACE1 and early-onset autosomal dominant Alzheimer disease.